Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

被引：0
|
作者：
Handy, Whitney F. [1 ]
Schmidt, Keith T. [2 ]
Price, Douglas K. [3 ]
Figg, William D. [2 ,3 ]
机构：
[1] Shenandoah Univ, Bernard J Dunn Sch Pharm, Fairfax, VA USA
[2] NCI, Clin Pharmacol Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
CANCER BIOLOGY & THERAPY | 2020年 / 21卷 / 09期
基金：
美国国家卫生研究院;
关键词：
ADT; docetaxel; CRPC; germline mutations; ANDROGEN-DEPRIVATION THERAPY; GENOTYPE;
D O I：
10.1080/15384047.2020.1796195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.
引用
收藏
页码：782 / 784
页数：3
相关论文
共 50 条
  • [1] HSD3B1 polymorphism and genomic HSD3B1 aberrations in prostate cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Sekino, Yohei
    Tsukahara, Shigehiro
    Nagakawa, Shohei
    Takamatsu, Dai
    Abe, Tatsuro
    Kinoshita, Fumio
    Ueda, Shohei
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Takeuchi, Ario
    Inokuchi, Junichi
    Uchiumi, Takeshi
    Oda, Yoshinao
    Eto, Masatoshi
    CANCER SCIENCE, 2022, 113 : 1591 - 1591
  • [2] HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer
    Alyamani, Mohammad
    Emamekhoo, Hamid
    Park, Sunho
    Taylor, Jennifer
    Almassi, Nima
    Upadhyay, Sunil
    Tyler, Allison
    Berk, Michael P.
    Hwang, Tae Hyun
    Grivas, Petros
    Rini, Brian
    Garcia, Jorge
    Auchus, Richard J.
    Sharifi, Nima
    CANCER RESEARCH, 2018, 78 (13)
  • [3] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Daniel Hettel
    Nima Sharifi
    Nature Reviews Urology, 2018, 15 : 191 - 196
  • [4] HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
    Hettel, Daniel
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2018, 15 (03) : 191 - 196
  • [5] HSD3B1 variant confers inferior ADT outcomes
    Peter Sidaway
    Nature Reviews Urology, 2016, 13 : 632 - 632
  • [6] HSD3B1 variant confers inferior ADT outcomes
    Sidaway, Peter
    NATURE REVIEWS UROLOGY, 2016, 13 (11) : 632 - 632
  • [7] Germline HSD3B1 Genetics and Prostate Cancer Outcomes
    Thomas, Lewis
    Sharifi, Nima
    UROLOGY, 2020, 145 : 13 - 21
  • [8] 3βHSD1 immunohistochemistry and HSD3B1 genotype in prostate cancer.
    Zhang, J. J. Haijing
    Nicolas, Marlo
    Hardaway, Aimalie
    Bohn, Kelsey
    Hettel, Daniel
    Klein, Eric A.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] HSD3B1, prostate cancer mortality and modifiable outcomes
    Freitas, Pedro F. S.
    Abdshah, Alireza
    McKay, Rana R.
    Sharifi, Nima
    NATURE REVIEWS UROLOGY, 2024,
  • [10] Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer
    Shiota, Masaki
    Fujimoto, Naohiro
    Sekino, Yohei
    Tsukahara, Shigehiro
    Nagakawa, Shohei
    Takamatsu, Dai
    Abe, Tatsuro
    Kinoshita, Fumio
    Ueda, Shohei
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Uchiumi, Takeshi
    Oda, Yoshinao
    Eto, Masatoshi
    ANDROLOGIA, 2022, 54 (01)
12345